ETR:MOR

MorphoSys (MOR) Stock Price, News & Analysis

€67.75
+0.05 (+0.07%)
(As of 04/22/2024 ET)
Today's Range
€67.70
€67.85
50-Day Range
€64.50
€67.95
52-Week Range
€14.52
€67.60
Volume
131,745 shs
Average Volume
153,687 shs
Market Capitalization
$2.55 billion
P/E Ratio
N/A
Dividend Yield
1.26%
Price Target
N/A
MOR stock logo

About MorphoSys Stock (ETR:MOR)

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

MOR Stock Price History

MOR Stock News Headlines

Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Novartis tender offer for MorphoSys AG commences
Novartis: Higher Guidance, Now A Buy
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
MorphoSys: Q4 Earnings Insights
MorphoSys just downgraded at JMP Securities, here's why
Novartis And MorphoSys Are A Perfect Match
MorphoSys AG ADR MOR
DAX Edges Higher As Investors Await GDP Data
European Shares Slightly Higher; Flash Eurozone GDP Data Awaited
See More Headlines
Receive MOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
524
Year Founded
N/A

Profitability

Net Income
$-189,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$238.28 million
Cash Flow
€130.69 per share
Book Value
€1.30 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.55 billion
Optionable
Not Optionable
Beta
0.61
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. Jean-Paul Kress M.D. (Age 59)
    Chairman of Management Board, MD & CEO
    Comp: $1.76M
  • Dr. Lucinda Crabtree Ph.D. (Age 45)
    CFO & Member of Management Board
    Comp: $705.82k
  • Ms. Charlotte Lohmann (Age 54)
    Chief Legal and Human Resources Officer & Member of Management Board
    Comp: $474.1k
  • Mr. Klaus De Wall
    Head of Accounting & Tax
  • Dr. Margit Urban
    Head of Discovery Alliances & Technologies
  • Dr. Julia Neugebauer Ph.D.
    Head of Investor Relations
  • Dr. Barbara Krebs-Pohl Ph.D.
    Chief Business Officer
  • Dr. Günter Wellnhofer
    Head of Technical Operations
  • Dr. Harald Watzka
    Head of Alliance Management
  • Ms. Yen Ching Chua
    Head of Clinical Operations

MOR Stock Analysis - Frequently Asked Questions

How have MOR shares performed in 2024?

MorphoSys' stock was trading at €34.00 at the beginning of the year. Since then, MOR stock has increased by 99.3% and is now trading at €67.75.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of MorphoSys own?
This page (ETR:MOR) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners